Fecal short-chain fatty acids in pregnancy and offspring asthma and allergic outcomes

Kathleen A. Lee-Sarwar; Rachel S. Kelly; Jessica Lasky-Su; Robert S. Zeiger; George T. O'Connor; Megan T. Sandel; Leonard B. Bacharier; Avraham Beigelman; Sheryl L. Rifas-Shiman; Vincent J. Carey; Benjamin J. Harshfield; Nancy Laranjo; Diane R. Gold; Scott T. Weiss; Augusto A. Litonjua

doi:10.1016/j.jaip.2019.08.036

Fecal short-chain fatty acids in pregnancy and offspring asthma and allergic outcomes

Kathleen A. Lee-Sarwar, Rachel S. Kelly, Jessica Lasky-Su, Robert S. Zeiger, George T. O'Connor, Megan T. Sandel, Leonard B. Bacharier, Avraham Beigelman, Sheryl L. Rifas-Shiman, Vincent J. Carey, Benjamin J. Harshfield, Nancy Laranjo, Diane R. Gold, Scott T. Weiss, Augusto A. Litonjua

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Original language	English
Pages (from-to)	1100-1102.e13
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	8
Issue number	3
DOIs	https://doi.org/10.1016/j.jaip.2019.08.036
State	Published - Mar 2020

Access to Document

10.1016/j.jaip.2019.08.036

Cite this

Lee-Sarwar, K. A., Kelly, R. S., Lasky-Su, J., Zeiger, R. S., O'Connor, G. T., Sandel, M. T., Bacharier, L. B., Beigelman, A., Rifas-Shiman, S. L., Carey, V. J., Harshfield, B. J., Laranjo, N., Gold, D. R., Weiss, S. T., & Litonjua, A. A. (2020). Fecal short-chain fatty acids in pregnancy and offspring asthma and allergic outcomes. Journal of Allergy and Clinical Immunology: In Practice, 8(3), 1100-1102.e13. https://doi.org/10.1016/j.jaip.2019.08.036

@article{56c80255cab341d6a056fa823428d933,

title = "Fecal short-chain fatty acids in pregnancy and offspring asthma and allergic outcomes",

author = "Lee-Sarwar, {Kathleen A.} and Kelly, {Rachel S.} and Jessica Lasky-Su and Zeiger, {Robert S.} and O'Connor, {George T.} and Sandel, {Megan T.} and Bacharier, {Leonard B.} and Avraham Beigelman and Rifas-Shiman, {Sheryl L.} and Carey, {Vincent J.} and Harshfield, {Benjamin J.} and Nancy Laranjo and Gold, {Diane R.} and Weiss, {Scott T.} and Litonjua, {Augusto A.}",

note = "Funding Information: The Vitamin D Antenatal Asthma Reduction Trial was funded by U01HL091528 from the National Heart, Lung, and Blood Institute. Additional funding came from National Institutes of Health grants R01HL108818, R01HL123915, R01HL141826-01, 5T32HL007427-34, and Environmental influences on Child Health Outcomes grant OD023268.Conflicts of interest: J. Lasky-Su is a consultant to Metabolon, Inc. R. S. Zeiger is a consultant for AstraZeneca, DBV Technologies, Genentech, Inc., GlaxoSmithKline, Novartis, Patara Pharma, Regeneron, TEVA Pharmaceuticals, and Theravance Biopharma, and has received research support from Aerocrine, AstraZeneca, Genentech, Inc., GlaxoSmithKline, National Heart, Lung, and Blood Institute, MedImmune, and Merck. G. T. O'Connor is a coinvestigator on a grant from Janssen Pharmaceuticals to Boston University that funds a study of the pathogenesis of chronic obstructive pulmonary disease. L. B. Bacharier participates on the Data Safety Monitoring Board of DBV Technologies. A. Beigelman holds stock from DBV Technologies. S. T. Weiss has received royalties from UpToDate, Inc. A. A. Litonjua has received author royalties from UpToDate, Inc. and consultant fees from AstraZeneca, LP. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: The Vitamin D Antenatal Asthma Reduction Trial was funded by U01HL091528 from the National Heart, Lung, and Blood Institute . Additional funding came from National Institutes of Health grants R01HL108818 , R01HL123915 , R01HL141826-01 , 5T32HL007427-34 , and Environmental influences on Child Health Outcomes grant OD023268 . ",

year = "2020",

month = mar,

doi = "10.1016/j.jaip.2019.08.036",

language = "English",

volume = "8",

pages = "1100--1102.e13",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

number = "3",

}

Lee-Sarwar, KA, Kelly, RS, Lasky-Su, J, Zeiger, RS, O'Connor, GT, Sandel, MT, Bacharier, LB, Beigelman, A, Rifas-Shiman, SL, Carey, VJ, Harshfield, BJ, Laranjo, N, Gold, DR, Weiss, ST & Litonjua, AA 2020, 'Fecal short-chain fatty acids in pregnancy and offspring asthma and allergic outcomes', Journal of Allergy and Clinical Immunology: In Practice, vol. 8, no. 3, pp. 1100-1102.e13. https://doi.org/10.1016/j.jaip.2019.08.036

TY - JOUR

T1 - Fecal short-chain fatty acids in pregnancy and offspring asthma and allergic outcomes

AU - Lee-Sarwar, Kathleen A.

AU - Kelly, Rachel S.

AU - Lasky-Su, Jessica

AU - Zeiger, Robert S.

AU - O'Connor, George T.

AU - Sandel, Megan T.

AU - Bacharier, Leonard B.

AU - Beigelman, Avraham

AU - Rifas-Shiman, Sheryl L.

AU - Carey, Vincent J.

AU - Harshfield, Benjamin J.

AU - Laranjo, Nancy

AU - Gold, Diane R.

AU - Weiss, Scott T.

AU - Litonjua, Augusto A.

N1 - Funding Information: The Vitamin D Antenatal Asthma Reduction Trial was funded by U01HL091528 from the National Heart, Lung, and Blood Institute. Additional funding came from National Institutes of Health grants R01HL108818, R01HL123915, R01HL141826-01, 5T32HL007427-34, and Environmental influences on Child Health Outcomes grant OD023268.Conflicts of interest: J. Lasky-Su is a consultant to Metabolon, Inc. R. S. Zeiger is a consultant for AstraZeneca, DBV Technologies, Genentech, Inc., GlaxoSmithKline, Novartis, Patara Pharma, Regeneron, TEVA Pharmaceuticals, and Theravance Biopharma, and has received research support from Aerocrine, AstraZeneca, Genentech, Inc., GlaxoSmithKline, National Heart, Lung, and Blood Institute, MedImmune, and Merck. G. T. O'Connor is a coinvestigator on a grant from Janssen Pharmaceuticals to Boston University that funds a study of the pathogenesis of chronic obstructive pulmonary disease. L. B. Bacharier participates on the Data Safety Monitoring Board of DBV Technologies. A. Beigelman holds stock from DBV Technologies. S. T. Weiss has received royalties from UpToDate, Inc. A. A. Litonjua has received author royalties from UpToDate, Inc. and consultant fees from AstraZeneca, LP. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: The Vitamin D Antenatal Asthma Reduction Trial was funded by U01HL091528 from the National Heart, Lung, and Blood Institute . Additional funding came from National Institutes of Health grants R01HL108818 , R01HL123915 , R01HL141826-01 , 5T32HL007427-34 , and Environmental influences on Child Health Outcomes grant OD023268 .

PY - 2020/3

Y1 - 2020/3

UR - http://www.scopus.com/inward/record.url?scp=85072288548&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2019.08.036

DO - 10.1016/j.jaip.2019.08.036

M3 - Article

C2 - 31494295

AN - SCOPUS:85072288548

SN - 2213-2198

VL - 8

SP - 1100-1102.e13

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 3

ER -

Fecal short-chain fatty acids in pregnancy and offspring asthma and allergic outcomes

Access to Document

Other files and links

Cite this